DOCSLIB.ORG

The PHI (PHI-27)

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
The PHI (PHI-27) Proc. NatL Acad. Sci. USA Vol. 80, pp. 895-898, February 1983 Neurobiology The PHI (PHI-27)/corticotropin-releasing factor/enkephalin immunoreactive hypothalamic neuron: Possible morphological basis for integrated control of prolactin, corticotropin, and growth hormone secretion (hypothalamic-pituitary hormones/release regulation/peptides/coexistence) T. HOKFELT*, J. FAHRENKRUGt, K. TATEMOTOt, V. MUTTS, S. WERNERO, A.-L. HULTINGO, L. TERENIUS1, AND K. J. CHANGII Departments of *Histology and *Biochemistry, Karolinska Institutet, Stockholm, Sweden; IDepartment of Endocrinology, Karolinska Hospital, Stockholm, Sweden; Department of Pharmacology, Uppsala University, Uppsala, Sweden; tDepartment of Clinical Chemistry, Fredrikborgs Central Hospital, Hiller6d, Denmark; and flWellcome Research Laboratories, Research Triangle Park, North Carolina 27709 Communicated by U. S. von Euler, November 1, 1982 ABSTRACT By using the indirect immunofluorescence tech- MATERIAL AND METHODS nique, one and the same neuron in the parvocellular part of the Male albino rats of the Sprague-Dawley strain (body weight, paraventricular nucleus has been shown to stain with antisera 150 g) were used. Untreated rats as well as colchicine-treated against three different peptides: PHI (PHI-27), corticotropin-re- rats were studied. The latter rats received an injection into the leasing factor (CRF), and enkephalin. This could explain the well- lateral ventricle of 120 ,ug of colchicine dissolved in 20 p1 of known parallel increase in plasma prolactin, corticotropin, and physiological saline. The rats were perfused with ice-cold for- growth hormone levels-for example, under certain types of malin, and the brains were dissected out, rinsed in 0.1 M phos- stress-as being due to a concomitant release of PHI-like, CRF- phate buffer with 5% sucrose added, and cut on a cryostat. The like, and enkephalin-like peptides from the same nerve endings sections were processed for the indirect immunofluorescence in the median eminence. A hypothetical mechanism for the co- technique (17). Briefly, series of adjacent sections (thickness, ordinated release of these three anterior pituitary hormones is 3, 6, 8, 10, or 14 1m) were incubated at 40C in a humid at- discussed. mosphere with antiserum to PHI, CRF, or [Met]enkephalin for 18-24 hr. rinsed, incubated with fluorescein isothiocyanate- or It has been shown that vasoactive intestinal polypeptide (VIP) tetramethyl rhodamine-conjugated sheep anti-rabbit antibod- (1, 2) causes release ofprolactin from the anterior pituitary gland ies, rinsed, mounted, and examined in a fluorescence micro- in vitro (3-5) and in vivo (6). Therefore, this peptide may rep- scope. The production of the enkephalin antisera has been de- resent a candidate for the prolactin-releasing factor (7, 8). How- scribed (18, 19). The CRF antiserum was purchased from Penin- ever, immunohistochemical studies have so far revealed only sula Laboratories (San Carlos, CA). The PHI antiserum was single VIP-positive nerve fibers in the medial basal hypothal- raised against PHI conjugated to bovine serum albumin. It amus, including the median eminence (9-12), from which the crossreacts with VIP and secretin to a very limited extent but hypothalamic-releasing hormone and inhibitory hormone are does not display crossreactivity with a number of other pep- released into the hypophysial portal blood vessels for transport tides, including [Leu]enkephalin and [Met]enkephalin and glu- to the anterior pituitary. More recently it has been demon- cagon (unpublished data). strated that PHI-like immunoreactivity [PHI-27; the peptide In some cases the restaining technique of Tramu et aL (20) (P) having NH2-terminal histidine (H) and COOH-terminal iso- was used to investigate the presence of more than one com- leucine (I) amide and 27 amino acid residues] (13) is present in pound in the same neuron. Briefly, after photography of the a parvocellular paraventriculo-infundibular system, forming a PHI staining patterns, removal ofthe coverslip, and rinsing in dense fiber network around the portal capillaries (14). PHI has phosphate-buffered saline, the sections were immersed in acid considerable structural similarities to VIP (13) and causes pro- potassium permanganate, rinsed, incubated with fluorescein lactin release, although it is less potent than VIP in this respect isothiocyanate-conjugated antiserum (as control), and, if nega- (unpublished data). tive, incubated with enkephalin or CRF antiserum. This pro- In the present communication we report that at least part of cedure was repeated and the final incubation was made with the PHI immunoreactive neurons in the parvocellular periven- CRF or, alternatively, enkephalin antiserum. For control pur- tricular hypothalamic nuclei contain two other peptides, one poses the antisera were pretreated with an excess of the re- enkephalin-like peptide (15) and one corticotropin-releasing spective peptide (50 pug ofpeptide per ml ofantiserum diluted factor (CRF)-like peptide (16). These PHI/CRF/enkephalin 1:10 or 1:100). This abolished all staining patterns described immunoreactive neurons may be involved in the integration of below. Furthermore, each antiserum was pretreated with an control ofprolactin, corticotropin (ACTH), and growth hormone excess ofeither ofthe other peptides (concentrations as above), (GH) secretion. Abbreviations: PHI, PHI-27, the peptide (P) having NH2-terminal his- The publication costs ofthis article were defrayed in part by page charge tidine (H) and COOH-terminal isoleucine (I) amide and 27 amino acid payment. This article must therefore be hereby marked "advertise- residues; VIP, vasoactive intestinal polypeptide; CRF, corticotropin- ment" in accordance with 18 U. S. C. §1734 solely to indicate this fact. releasing factor; ACTH, corticotropin; GH, growth hormone. 895 Downloaded by guest on September 25, 2021 896 Neurobiology: Hokfelt et al. Proc. Nad Acad. Sci. USA 80 (1983) and this treatment did not change the staining patterns de- scribed below. RESULTS Numerous PHI and CRF immunoreactive cell bodies were seen mainly in the parvocellular part ofthe paraventricular nucleus. On adjacent sections enkephalin immunoreactive perikarya were seen with a similar distribution, but many cells containing this immunoreactivity were seen also in other hypothalamic areas. In the median eminence a dense network of PHI, CRF, and enkephalin immunoreactive fibers was observed in the ex- ternal layer extending along the entire length of this structure into the stalk. Again, enkephalin immunoreactive fibers were seen in many other structures, whereas PHI and CRF had a much more restricted distribution and occurred only in a few other areas in the hypothalamus. Analysis ofthin adjacent sections revealed that in many cases all three immunoreactivities were present in the same neuronal cell bodies. This was confirmed by the elution-restaining ex- periments, in which certain cells in the parvocellular paraven- tricular nucleus were first demonstrated to contain PHI-like (Fig. la), then enkephalin-like (Fig. lb), and finally also CRF- like (Fig. 1c) immunoreactivities. There were also cells that seemed to contain either only enkephalin-like or only PHI-like and CRF-like or only enkephalin-like and CRF-like immuno- reactivities (Fig. 1 a-c). The staining patterns ofthe three pep- tides in the median eminence were similar, but due to the small size of the fibers, identity could not be established. DISCUSSION Itwas demonstrated earlier that the parvocellular paraventricu- lar nucleus ofthe rat contains enkephalin (21-23), CRF (24, 25), and PHI (14) immunoreactive neurons, but these studies dealt with only one peptide at the time and thus the question of oc- currence in one and the same neuron was not addressed. The present findings demonstrate that one and the same neuron in the parvocellular part ofthe paraventricular nucleus can contain at least three compounds-a PHI-like, a CRF-like, and an en- kephalin-like peptide. However, some cells seemed to contain only one or, alternatively, two of these peptides. Whether this is true or whether the apparent absence of peptide is due to insufficient sensitivity of our technique remains to be eluci- dated. According to the classical concept ofHarris (26), the hormone secretion from the anterior pituitary is controlled by hypotha- lamic factors released into the hypophysial portal system and transported to the gland. Each pituitary hormone may be con- trolled by releasing or inhibitory factor(s), or both (27, 28). It is well known that under some conditions, there is a parallel increase in release of several pituitary hormones. Thus, it has been reported that certain types of stress cause release ofboth ACTH and prolactin (29-32) and of ACTH and GH (33). The FIG. 1. Immunofluorescence micrographs of the paraventricular nucleus of a colchicine-treated rat after incubation with antiserum to PHI (a), enkephalin (ENK) (b), and CRF (c). All micrographs show the same section, which, afterphotography of thefirstdistribution pattern (PHI), has been subjected to elution and restaining with antiserum to the next antigen (CRF) and then to the third one (ENK). Note that many cells (single arrowhead) are immunoreactive to all three peptides but that some exhibit only PHI-like and CRF-like immunoreactivity (double arrowheads), some only ENK-like immunoreactivity (triple arrowheads), and some ENK-like and CRF-like immunoreactivity (quadruple arrowheads). The apparent presence of only one or two pep- tides must
Load more

Recommended publications
  • Secretin and Autism: a Clue but Not a Cure
    SCIENCE & MEDICINE Secretin and Autism: A Clue But Not a Cure by Clarence E. Schutt, Ph.D. he world of autism has been shaken by NBC’s broadcast connections could not be found. on Dateline of a film segment documenting the effect of Tsecretin on restoring speech and sociability to autistic chil- The answer was provided nearly one hundred years ago by dren. At first blush, it seems unlikely that an intestinal hormone Bayless and Starling, who discovered that it is not nerve signals, regulating bicarbonate levels in the stomach in response to a but rather a novel substance that stimulates secretion from the good meal might influence the language centers of the brain so cells forming the intestinal mucosa. They called this substance profoundly. However, recent discoveries in neurobiology sug- “secretin.” They suggested that there could be many such cir- gest several ways of thinking about the secretin-autism connec- culating substances, or molecules, and they named them “hor- tion that could lead to the breakthroughs we dream about. mones” based on the Greek verb meaning “to excite”. As a parent with more than a decade of experience in consider- A simple analogy might help. If the body is regarded as a commu- ing a steady stream of claims of successful treatments, and as a nity of mutual service providers—the heart and muscles are the pri- scientist who believes that autism is a neurobiological disorder, I mary engines of movement, the stomach breaks down foods for have learned to temper my hopes about specific treatments by distribution, the liver detoxifies, and so on—then the need for a sys- seeing if I could construct plausible neurobiological mechanisms tem of messages conveyed by the blood becomes clear.
    [Show full text]
  • Growth Hormone-Releasing Hormone in Lung Physiology and Pulmonary Disease
    cells Review Growth Hormone-Releasing Hormone in Lung Physiology and Pulmonary Disease Chongxu Zhang 1, Tengjiao Cui 1, Renzhi Cai 1, Medhi Wangpaichitr 1, Mehdi Mirsaeidi 1,2 , Andrew V. Schally 1,2,3 and Robert M. Jackson 1,2,* 1 Research Service, Miami VAHS, Miami, FL 33125, USA; [email protected] (C.Z.); [email protected] (T.C.); [email protected] (R.C.); [email protected] (M.W.); [email protected] (M.M.); [email protected] (A.V.S.) 2 Department of Medicine, University of Miami Miller School of Medicine, Miami, FL 33101, USA 3 Department of Pathology and Sylvester Cancer Center, University of Miami Miller School of Medicine, Miami, FL 33101, USA * Correspondence: [email protected]; Tel.: +305-575-3548 or +305-632-2687 Received: 25 August 2020; Accepted: 17 October 2020; Published: 21 October 2020 Abstract: Growth hormone-releasing hormone (GHRH) is secreted primarily from the hypothalamus, but other tissues, including the lungs, produce it locally. GHRH stimulates the release and secretion of growth hormone (GH) by the pituitary and regulates the production of GH and hepatic insulin-like growth factor-1 (IGF-1). Pituitary-type GHRH-receptors (GHRH-R) are expressed in human lungs, indicating that GHRH or GH could participate in lung development, growth, and repair. GHRH-R antagonists (i.e., synthetic peptides), which we have tested in various models, exert growth-inhibitory effects in lung cancer cells in vitro and in vivo in addition to having anti-inflammatory, anti-oxidative, and pro-apoptotic effects. One antagonist of the GHRH-R used in recent studies reviewed here, MIA-602, lessens both inflammation and fibrosis in a mouse model of bleomycin lung injury.
    [Show full text]
  • Inhibition of Gastrin Release by Secretin Is Mediated by Somatostatin in Cultured Rat Antral Mucosa
    Inhibition of gastrin release by secretin is mediated by somatostatin in cultured rat antral mucosa. M M Wolfe, … , G M Reel, J E McGuigan J Clin Invest. 1983;72(5):1586-1593. https://doi.org/10.1172/JCI111117. Research Article Somatostatin-containing cells have been shown to be in close anatomic proximity to gastrin-producing cells in rat antral mucosa. The present studies were directed to examine the effect of secretin on carbachol-stimulated gastrin release and to assess the potential role of somatostatin in mediating this effect. Rat antral mucosa was cultured at 37 degrees C in Krebs-Henseleit buffer, pH 7.4, gassed with 95% O2-5% CO2. After 1 h the culture medium was decanted and mucosal gastrin and somatostatin were extracted. Carbachol (2.5 X 10(-6) M) in the culture medium increased gastrin level in the medium from 14.1 +/- 2.5 to 26.9 +/- 3.0 ng/mg tissue protein (P less than 0.02), and decreased somatostatin-like immunoreactivity in the medium from 1.91 +/- 0.28 to 0.62 +/- 0.12 ng/mg (P less than 0.01) and extracted mucosal somatostatin-like immunoreactivity from 2.60 +/- 0.30 to 1.52 +/- 0.16 ng/mg (P less than 0.001). Rat antral mucosa was then cultured in the presence of secretin to determine its effect on carbachol-stimulated gastrin release. Inclusion of secretin (10(-9)-10(-7) M) inhibited significantly carbachol-stimulated gastrin release into the medium, decreasing gastrin from 26.9 +/- 3.0 to 13.6 +/- 3.2 ng/mg (10(-9) M secretin) (P less than 0.05), to 11.9 +/- 1.7 ng/mg (10(-8) secretin) (P less than 0.02), and to 10.8 +/- 4.0 ng/mg (10(-7) M secretin) (P less than […] Find the latest version: https://jci.me/111117/pdf Inhibition of Gastrin Release by Secretin Is Mediated by Somatostatin in Cultured Rat Antral Mucosa M.
    [Show full text]
  • Secretin/Vasoactive Intestinal Peptide-Stimulated Secretion of Bombesin/ Gastrin Releasing Peptide from Human Small Cell Carcinoma of the Lung1
    ICANCER RESEARCH 46, 1214-1218, March 1986] Secretin/Vasoactive Intestinal Peptide-stimulated Secretion of Bombesin/ Gastrin Releasing Peptide from Human Small Cell Carcinoma of the Lung1 Louis Y. Korman,2 Desmond N. Carney, Marc L. Citron, and Terry W. Moody Medica/ Service (151W), Veterans Administration Medical Center, Washington, DC 20422 [L. Y.K., M.L.C.]; Department of Medicine and Biochemistry George Washington University School of Medicine, Washington, DC 20037 [T. W. M.¡;and National Cancer Institute-Navy Medical Oncology Branch National Cancer Institute and National Naval Medical Center, Bethesda, Maryland [D. N. C.¡ ABSTRACT autocrine factor for SCCL (12) growth. We studied the mecha nism of BLI secretion in several SCCL cell lines by examining Bombesin/gastrin releasing peptide-like immunoreactivity (BLI) the action of agents that increase intracellular cAMP. is found in the majority of small cell carcinoma of the lung (SCCL) Because of the results of these in vitro studies and the fact cell lines examined. Because BLI is present in high concentration that secretin stimulates hormone release in patients with gastrin in SCCL we studied the mechanism of BLI secretion from several producing tumors (Zollinger-Ellison syndrome), we examined the SCCL cell lines and in patients with SCCL. In cell line NCI-H345 action of i.v. secretin infusion on plasma BLI levels in several the structurally related polypeptide hormones secretin, vasoac- patients with SCCL, non-SCCL lung tumors, and patients with tive intestinal peptide, and peptide histidine isoleucine as well as theophylline, a phosphodiesterase inhibitor, N6,O2'-dibutyryl out any cancer. cyclic adenosine 3':5'-monophosphate, a cyclic nucleotide ana logue, increased BLI release by 16-120% and cyclic adenosine MATERIALS AND METHODS 3':5'-monophosphate by 36-350%.
    [Show full text]
  • The Role of Corticotropin-Releasing Hormone at Peripheral Nociceptors: Implications for Pain Modulation
    biomedicines Review The Role of Corticotropin-Releasing Hormone at Peripheral Nociceptors: Implications for Pain Modulation Haiyan Zheng 1, Ji Yeon Lim 1, Jae Young Seong 1 and Sun Wook Hwang 1,2,* 1 Department of Biomedical Sciences, College of Medicine, Korea University, Seoul 02841, Korea; [email protected] (H.Z.); [email protected] (J.Y.L.); [email protected] (J.Y.S.) 2 Department of Physiology, College of Medicine, Korea University, Seoul 02841, Korea * Correspondence: [email protected]; Tel.: +82-2-2286-1204; Fax: +82-2-925-5492 Received: 12 November 2020; Accepted: 15 December 2020; Published: 17 December 2020 Abstract: Peripheral nociceptors and their synaptic partners utilize neuropeptides for signal transmission. Such communication tunes the excitatory and inhibitory function of nociceptor-based circuits, eventually contributing to pain modulation. Corticotropin-releasing hormone (CRH) is the initiator hormone for the conventional hypothalamic-pituitary-adrenal axis, preparing our body for stress insults. Although knowledge of the expression and functional profiles of CRH and its receptors and the outcomes of their interactions has been actively accumulating for many brain regions, those for nociceptors are still under gradual investigation. Currently, based on the evidence of their expressions in nociceptors and their neighboring components, several hypotheses for possible pain modulations are emerging. Here we overview the historical attention to CRH and its receptors on the peripheral nociception and the recent increases in information regarding their roles in tuning pain signals. We also briefly contemplate the possibility that the stress-response paradigm can be locally intrapolated into intercellular communication that is driven by nociceptor neurons.
    [Show full text]
  • Interactions Between Two Different G Protein-Coupled Receptors in Reproductive Hormone-Producing Cells: the Role of PACAP and Its Receptor PAC1R
    International Journal of Molecular Sciences Review Interactions between Two Different G Protein-Coupled Receptors in Reproductive Hormone-Producing Cells: The Role of PACAP and Its Receptor PAC1R Haruhiko Kanasaki *, Aki Oride, Tomomi Hara, Tselmeg Mijiddorj, Unurjargal Sukhbaatar and Satoru Kyo Department of Obstetrics and Gynecology, School of Medicine, Shimane University, 89-1 Enya-cho, Izumo, Shimane 693-8501, Japan; [email protected] (A.O.); [email protected] (T.H.); [email protected] (T.M.); [email protected] (U.S.); [email protected] (S.K.) * Correspondence: [email protected]; Tel.: +81-853-20-2268; Fax: +81-853-20-2264 Academic Editor: Kathleen Van Craenenbroeck Received: 18 August 2016; Accepted: 19 September 2016; Published: 26 September 2016 Abstract: Gonadotropin-releasing hormone (GnRH) and gonadotropins are indispensable hormones for maintaining female reproductive functions. In a similar manner to other endocrine hormones, GnRH and gonadotropins are controlled by their principle regulators. Although it has been previously established that GnRH regulates the synthesis and secretion of luteinizing hormone (LH) and follicle-stimulating hormone (FSH)—both gonadotropins—from pituitary gonadotrophs, it has recently become clear that hypothalamic GnRH is under the control of hypothalamic kisspeptin. Prolactin, which is also known as luteotropic hormone and is released from pituitary lactotrophs, stimulates milk production in mammals. Prolactin is also regulated by hypothalamic factors, and it is thought that prolactin synthesis and release are principally under inhibitory control by dopamine through the dopamine D2 receptor. In addition, although it remains unknown whether it is a physiological regulator, thyrotropin-releasing hormone (TRH) is a strong secretagogue for prolactin.
    [Show full text]
  • Secretin/Secretin Receptors
    JKVTAMand others Secretin and secretin receptor 52:3 T1–T14 Thematic Review evolution MOLECULAR EVOLUTION OF GPCRS Secretin/secretin receptors Correspondence Janice K V Tam, Leo T O Lee, Jun Jin and Billy K C Chow should be addressed to B K C Chow School of Biological Sciences, The University of Hong Kong, Pokfulam Road, Hong Kong, Hong Kong Email [email protected] Abstract In mammals, secretin is a 27-amino acid peptide that was first studied in 1902 by Bayliss and Key Words Starling from the extracts of the jejunal mucosa for its ability to stimulate pancreatic " secretin secretion. To date, secretin has only been identified in tetrapods, with the earliest diverged " secretin receptor secretin found in frogs. Despite being the first hormone discovered, secretin’s evolutionary " evolution origin remains enigmatic, it shows moderate sequence identity in nonmammalian tetrapods " origin but is highly conserved in mammals. Current hypotheses suggest that although secretin has " divergence already emerged before the divergence of osteichthyans, it was lost in fish and retained only in land vertebrates. Nevertheless, the cognate receptor of secretin has been identified in both actinopterygian fish (zebrafish) and sarcopterygian fish (lungfish). However, the zebrafish secretin receptor was shown to be nonbioactive. Based on the present information that the earliest diverged bioactive secretin receptor was found in lungfish, and its ability to interact with both vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide potently suggested that secretin receptor was descended from a VPAC-like receptor gene before the Actinopterygii–Sarcopterygii split in the vertebrate lineage. Hence, Journal of Molecular Endocrinology secretin and secretin receptor have gone through independent evolutionary trajectories despite their concurrent emergence post-2R.
    [Show full text]
  • Secretin: Structure of the Precursor and Tissue Distribution of the Mrna (Intestine/Preprohormone/Cdna/Polymerase Chain Reaction) ALAN S
    Proc. Nati. Acad. Sci. USA Vol. 87, pp. 2299-2303, March 1990 Biochemistry Secretin: Structure of the precursor and tissue distribution of the mRNA (intestine/preprohormone/cDNA/polymerase chain reaction) ALAN S. KoPIN*, MICHAEL B. WHEELER, AND ANDREW B. LEITER Division of Gastroenterology, Department of Medicine, New England Medical Center, Boston, MA 02111 Communicated by Donald F. Steiner, January 5, 1990 (receivedfor review, November 17, 1989) ABSTRACT Secretin is a 27-amino acid gastrointestinal denum, while the levels reported for hypothalamus, thala- hormone that stimulates the secretion of bicarbonate-rich mus, and olfactory lobe were comparable to those in small pancreatic fluid. The unusually high number ofserine, leucine, intestine (9). Others report that brain contains either small and arginine residues in secretin has precluded the use of amounts (10, 11) or no secretin-like immunoreactivity (12). oligonucleotides to screen cDNA libraries to isolate a secretin In the present study, we have isolated cDNAs encoding the cDNA. In the present study, a short cDNA encoding porcine rat and porcine secretin precursors.t The deduced amino acid secretin was amplified from duodenal mucosal first-strand sequence includes a signal peptide, an N-terminal peptide, cDNA template by using 16,384- and 4096-fold degenerate secretin, and a 72-amino acid C-terminal peptide. We have primers in the DNA polymerase chain reaction. From the used the secretin cDNA as a probe in Northern blot hybrid- sequence of the amplified cDNA, an unambiguous oligonucle- izations to address unresolved questions regarding the tissue otide probe was designed to screen a cDNA library. Here we localization of secretin biosynthesis in the rat CNS and report the sequences of cDNAs encoding the porcine and rat gastrointestinal tract.
    [Show full text]
  • Downloaded from Bioscientifica.Com at 09/27/2021 12:13:16PM Via Free Access 82 C Y Y CHENG, J Y S CHU and Others
    81 REVIEW Vasopressin-independent mechanisms in controlling water homeostasis Carrie Y Y Cheng*, Jessica Y S Chu* and Billy K C Chow School of Biological Sciences, The University of Hong Kong, Pokfulam, Hong Kong SAR, People’s Republic of China (Correspondence should be addressed to B K C Chow; Email: [email protected]) *(C Y Y Cheng and J Y S Chu contributed equally this work) Abstract The maintenance of body water homeostasis depends on the balance between water intake and water excretion. In the kidney, vasopressin (Vp) is a critical regulator of water homeostasis by controlling the insertion of aquaporin 2 (AQP2) onto the apical membrane of the collecting duct principal cells in the short term and regulating the gene expression of AQP2 in the long term. A growing body of evidence from both in vitro and in vivo studies demonstrated that both secretin and oxytocin are involved as Vp-independent mechanisms regulating the renal water reabsorption process, including the translocation and expression of AQP2. This review focuses on how these two hormones are potentially involved as Vp-independent mechanisms in controlling water homeostasis. Journal of Molecular Endocrinology (2009) 43, 81–92 Introduction sensation of thirst and the availability of water, and water excretion controlled by the antidiuretic hormone Osmoregulation involves sophisticatedly integrated Vp and the medullary osmotic gradient. physiological and behavioral responses to maintain the osmolality of the fluid bathing body cells. The regulation of renal handling of water and electrolytes by Vasopressin the antidiuretic hormone, vasopressin (Vp), and the regulation of water and salt intake by the dipsogenic Vp is a pleiotropic peptide which affects a wide range of peptide, angiotensin, are involved in the physiological peripheral and central regulated functions in order to and behavioral approaches respectively.
    [Show full text]
  • Oxytocin Using ALZET Osmotic Pumps
    ALZET® Bibliography References on the Administration of Oxytocin Using ALZET Osmotic Pumps Q8212: T. Iwasa, et al. The effects of chronic oxytocin administration on body weight and food intake in DHT-induced PCOS model rats. Gynecol Endocrinol 2020;36(1):55-60 Agents: Oxytocin Vehicle: Saline; Route: SC; Species: Rat; Pump: 2002; Duration: 14 days; ALZET Comments: Dose (380 ug/day); Controls received mp w/ vehicle; animal info (Female Wistar rats); replacement therapy (effects of the chronic administration of oxytocin); Q8208: T. Hirayama, et al. Oxytocin induced labor causes region and sex-specific transient oligodendrocyte cell death in neonatal mouse brain. J Obstet Gynaecol Res 2020;46(1):66-78 Agents: Oxytocin Vehicle: Buffered Saline; Route: SC; Species: Mice; Pump: 1003D; Duration: Not stated; ALZET Comments: Dose (0.6, 6, 18 or 240 μg/day); Controls received mp w/ vehicle; animal info (Wild-type C57BL6/J mice and DBA/2 mice); replacement therapy ( associations between oxytocin induced labor and mental disorders in offspring); Q7621: M. Janecek, et al. Oxytocin facilitates adaptive fear and attenuates anxiety responses in animal models and human studies-potential interaction with the corticotropin-releasing factor (CRF) system in the bed nucleus of the stria terminalis (BNST). Cell and Tissue Research 2019;375(1):143-172 Agents: Oxytocin; atosiban Vehicle: Not Stated; Route: CSF/CNS (lateral ventricle); Species: Mice; Rats; Pump: Not Stated; Duration: 15 days; 14 days; ALZET Comments: Dose (Oxytocin 1, 10 ng/h), (atosiban 600μg/kg/day)); animal info (adult, male); behavioral testing (elevated plus maze, light-dark box, chronic subordinate colony stress); Atosiban is an inhibitor of the hormones oxytocin and vasopressin; literature review: author lists studies where oxytocin was administered to mice and atosiban was administered to rats; Q7962: C.
    [Show full text]
  • A Bombesin Immunoreactive Peptidein Milk
    Proc. Natl. Acad. Sci. USA Vol. 81, pp. 578-582, January 1984 Medical Sciences A bombesin immunoreactive peptide in milk (radioinimunoassay/gel filtration/high-performance liquid chromatography) GLORIA D. JAHNKE* AND LAWRENCE H. LAZARUSt Peptide Neurochemistry Workgroup, Laboratory of Behavioral and Neurological Toxicology, National Institute of Environmental Health Sciences, Research Triangle Park, NC 27709 Communicated by George H. Hitchings, September 19, 1983 ABSTRACT Immunoreactivity to the amphibian peptide tains peptide and steroid hormones (32), prostaglandins (33), bombesin was found in instant nonfat dry milk (ca. 0.7 ng/ml) morphine (34), melatonin (35), and immunoglobulins (36) in and in the whey of whole or skim bovine milk (ca. 1.2 ng/ml) addition to a growth factor and enzymes (37, 38). even after ultracentrifugation. The soluble immunoreactivity Moreover, the peptide hormones and the growth factor re- was associated with a peptide exhibiting the following charac- tain their biological activities in milk (37, 39, 40) and, when teristics: (i) parallel displacement in an immunoassay using an ingested by the neonate, appear intact in plasma (35, 39-42). antiserum recognizing bombesin amino acid residues 5-8; (ii) Thus, considering the coincidence between the action of am- separation from both gastrin-releasing peptide and amphibian phibian bombesin and milk on hormone peptide levels, we bombesin by gel filtration-the approximate Mr was 3,200; sought to determine whether milk could be a source of a (iii) denaturation in urea,
    [Show full text]
  • SECRETIN ENHANCED MRCP Andrew T
    SECRETIN ENHANCED MRCP Andrew T. Trout, MD @AndrewTroutMD Relevant Disclosures • Grant support: – National Pancreas Foundation • In-kind grant support: – ChiRhoClin, Inc. Objectives • Review basics of secretin and its role in diagnosis of pediatric pancreatic disease • Describe techniques for performing and interpreting secretin-enhanced MRCP Pediatric Pancreatic Disease • Endocrine insufficiency • Exocrine insufficiency • Pancreatitis Pediatric Pancreatic Disease • Endocrine insufficiency • Exocrine insufficiency • Pancreatitis Pediatric Pancreatic Disease • Multiple hereditary causes of exocrine insufficiency • Increasing recognition of acute recurrent (ARP) and chronic pancreatitis (CP) as causes of exocrine insufficiency – 1-5 per 100,000 • Increasing recognition of genetic causes of ARP and CP Secretin • Secretin plays a role in assessment of pediatric pancreatic disease – Increase duct visibility – Duct stress test – Assess exocrine fxn – Perfusion effect? Manfredi R, et al. Radiology. 2002 Sep;224(3):675-82. nature.com Secretin Basics • In broad terms: Adds value only* for pancreatic imaging • Synthetic human secretin – 0.2 µg / kg, max 16 µg – Test dose (atopy, asthma) – Slow injection over 1 minute (abd pain, vomiting) – Contraindications – acute pancreatitis, allergy • Mechanisms: – Bicarbonate secretion – Transient increase in tone at the sphincter of Oddi • Plasma half-life = 3-5 min – Duration of effect >10 min • Cost = up to $2000/vial Afroze S, et al. Ann Transl Med. 2013 Oct;1(3):29. Secretin Basics • In broad terms: Adds value only* for pancreatic imaging • Synthetic human secretin – 27 amino acid polypeptide – 0.2 µg / kg, max 16 µg – Test dose (atopy, asthma) – Slow injection over 1 minute (abd pain, vomiting) – Contraindications – acute pancreatitis, allergy • Mechanisms: – Bicarbonate secretion – Transient increase in tone at the sphincter of Oddi • Plasma half-life = 3-5 min – Duration of effect >10 min Matsufuji H, et al.
    [Show full text]